10X Genomics Hits New 52-Week High of $47.25, Up 112.8% Year-Over-Year

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 47.25 on July 21, 2026. This achievement marks a remarkable 112.8% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 19.09% during the same period. With a market capitalization of USD 2,489 million, 10X Genomics operates in a competitive industry characterized by rapid innovation and development. The company's financial metrics reveal a price-to-book ratio of 3.13, indicating how the market values its assets relative to its stock price. However, it is important to note that the company is currently loss-making, as reflected in its negative return on equity of -10.80% and a debt-to-equity ratio of -0.64. The stock's previous 52-week low was recorded at USD 11.16, highlighting the significant growth trajectory the company has experienced over the past year. This upward movement underscores the evolving landscape of the biotechnology sector and the potential for continued advancements.